All In Biotech

Drug Trial Radar · NCT07090954

A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma

An Open-Label, Multicenter, Phase Ib/II Clinical Trial of GR1803 Injection in Combination With an Anti-CD38 Monoclonal Antibody Evaluating Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy in Subjects With Relapsed/Refractory Multiple Myeloma Previously Treated With at Least One Line of Therapy Including Lenalidomide and a Proteasome Inhibitor

Last checked: Nov 19, 2026Latest source record: Jul 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Aug 31, 2025

Primary completion

Jul 31, 2026

Study completion Jan 31, 2030

Sponsor

Sponsor type
Industry
First posted
Jul 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to identify recommended Phase 3 doses (RP3D) for treatment combination (GR1803 injection plus anti-CD38 monoclonal antibody) and to characterize the efficacy of RP3D for the treatment combination.

Conditions

  • Multiple Myeloma

Interventions

  • GR1803 injectionDrug

    Participants will receive GR1803 injection.

  • Anti-CD38 Monoclonal AntibodyDrug

    Participants will receive anti-CD38 monoclonal antibody.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation: Number of Participants With Dose Limiting Toxicity (DLT)Time frame: Up to 2 Years
  2. Dose escalation: Number of Participants With Adverse Events and Serious Adverse EventsTime frame: Up to 2 Years
  3. Dose expansion: Overall Response RateTime frame: Up to 2 Years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Shanghai Fourth People's Hospital Affiliated with Tongji University

    Shanghai, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.